Clercq Casper L. De Net Worth

What's Clercq De's mailing address?

Clercq's mailing address filed with the SEC is 525 University Ave #800, Palo Alto, CA 94301, USA.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over 124,847,276$ worth of iRhythm Technologies Inc stock and bought 150,000 units worth 2,550,000$ . The most active insiders traders include Holdings A/S Novo、Vijay K Lathi、Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of 1,872,546$. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth 96,506$.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO